| 摘要 |
Novel spiro-polycyclicimidazolidinedione derivatives useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. The derivatives include 2',3'-dihydro-spiro[imidazolidine-4,4'-[4'H]-naphtho[1,2-b]pyran]-2,5- dione, 2',3'-dihydro-spiro-[imidazolidine-4, 4'-[4'H]-naphtho[1,2-b]thiopyran]-2,5-dione, 1',2',3',4'-tetrahydro-spiro[imidazolidine-4,1'-benz[a]anthracene]2,5- dione, 2',3'-dihydro-spiro[imidazolidine-4,1'phenalene]-2,5-dione, 1',2',3',4'-tetrahydro-spiro[imidazolidine-4,1'-phenanthrene]-2,5-dione, the 2,1 isomers of the 2',3'-dihydro-4'H-pyran and 2',3'-dihydro-4'H-thiopyran derivatives, the 2',3'-dihydro-4'H-anthracenopyran and 2',3'-dihydro-4'H-anthracenothiopyran derivatives, the spiro-4,4' isomer of the tetrahydrophenanthrene derivative, the [b] isomer of the benzanthracene derivative and the mono or disubstituted 2',3'-dihydro-4'H-naphthopyran, 2',3'-dihydro-4'H-naphthothiopyran and tetrahydrophenanthrene derivatives. |
